Gene Association: CDYL
UniProt Search:
CDYL (PROTEIN_CODING)
Function Description: chromodomain Y like
found 5 associated metabolites with current gene based on the text mining result from the pubmed database.
Crotonoyl-CoA
Crotonoyl-CoA is an important component in several metabolic pathways, notably fatty acid and amino acid metabolism. It is the substrate of a group of enzymes acyl-Coenzyme A oxidases 1, 2, 3 (E.C.: 1.3.3.6) corresponding to palmitoyl, branched chain, and pristanoyl, respectively, in the peroxisomal fatty acid beta-oxidation, producing hydrogen peroxide. Abnormality of this group of enzymes is linked to coma, dehydration, diabetes, fatty liver, hyperinsulinemia, hyperlipidemia, and leukodystrophy. It is also a substrate of a group of enzymes called acyl-Coenzyme A dehydrogenase (E.C.:1.3.99-, including 1.3.99.2, 1.3.99.3) in the metabolism of fatty acids or branched chain amino acids in the mitochondria (Rozen et al., 1994). Acyl-Coenzyme A dehydrogenase (1.3.99.3) has shown to contribute to kidney-associated diseases, such as adrenogential syndrome, kidney failure, kidney tubular necrosis, homocystinuria, as well as other diseases including cretinism, encephalopathy, hypoglycemia, medium chain acyl-CoA dehydrogenase deficiency. The gene (ACADS) also plays a role in theta oscillation during sleep. In addition, crotonoyl-CoA is the substrate of enoyl coenzyme A hydratase (E.C.4.2.1.17) in the mitochondria during lysine degradation and tryptophan metabolism, benzoate degradation via CoA ligation; in contrast it is the product of this enzyme in the butanoate metabolism. Moreover, it is produced from multiple enzymes in the butanoate metabolism pathway, including 3-Hydroxybutyryl-CoA dehydratase (E.C.:4.2.1.55), glutaconyl-CoA decarboxylase (E.C.: 4.1.1.70), vinylacetyl-CoA Δ-isomerase (E.C.: 5.3.3.3), and trans-2-enoyl-CoA reductase (NAD+) (E.C.: 1.3.1.44). In lysine degradation and tryptophan metabolism, crotonoyl CoA is produced by glutaryl-Coenzyme A dehydrogenase (E.C.:1.3.99.7) lysine and tryptophan metabolic pathway. This enzyme is linked to type-1glutaric aciduria, metabolic diseases, movement disorders, myelinopathy, and nervous system diseases. [HMDB] Crotonoyl-CoA (CAS: 992-67-6) is an important component in several metabolic pathways, notably fatty acid and amino acid metabolism. It is the substrate of acyl-coenzyme A oxidases 1, 2, and 3 (EC 1.3.3.6) corresponding to palmitoyl, branched-chain, and pristanoyl, respectively. In peroxisomal fatty acid beta-oxidation, these enzymes produce hydrogen peroxide. Abnormalities in this group of enzymes are linked to coma, dehydration, diabetes, fatty liver, hyperinsulinemia, hyperlipidemia, and leukodystrophy. Crotonoyl-CoA is also a substrate of a group of enzymes called acyl-coenzyme A dehydrogenases (EC 1.3.99-, 1.3.99.2, 1.3.99.3) in the metabolism of fatty acids or branched-chain amino acids in the mitochondria (PMID: 7698750). Acyl-coenzyme A dehydrogenase has been shown to contribute to kidney-associated diseases, such as adrenogential syndrome, kidney failure, kidney tubular necrosis, homocystinuria, as well as other diseases including cretinism, encephalopathy, hypoglycemia, and medium-chain acyl-CoA dehydrogenase deficiency. The gene (ACADS) also plays a role in theta oscillation during sleep. In addition, crotonoyl-CoA is the substrate of enoyl-coenzyme A hydratase (EC 4.2.1.17) in the mitochondria during lysine degradation and tryptophan metabolism as well as benzoate degradation via CoA ligation. Crotonoyl-CoA is the product of this enzyme in butanoate metabolism. Moreover, it is produced from multiple enzymes in the butanoate metabolism pathway, including 3-hydroxybutyryl-CoA dehydratase (EC 4.2.1.55), glutaconyl-CoA decarboxylase (EC 4.1.1.70), vinylacetyl-CoA delta-isomerase (EC 5.3.3.3), and trans-2-enoyl-CoA reductase (NAD+) (EC 1.3.1.44). In lysine degradation and tryptophan metabolism, crotonoyl-CoA is produced by glutaryl-coenzyme A dehydrogenase (EC 1.3.99.7). This enzyme is linked to glutaric aciduria type I, metabolic diseases, movement disorders, myelinopathy, and nervous system diseases.
Fluphenazine decanoate
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Fluphenazine decanoate is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research[1][2][3].
CoA 4:1
Fluphenazine decanoate
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Fluphenazine decanoate is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research[1][2][3].
